| Species |
Mouse |
| Protein Construction |
RNF43 (Gly24-Tyr197)_x000D_
Accession # Q5NCP0 |
hFc |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Mouse R spondin 1, His Tag at 2μg/ml (100μl/Well) on the plate can bind RNF43 hFc Chimera, Mouse. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
45.6 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 53-60 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
RNF43 (E3 ubiquitin-protein ligase RNF43 or RING-type E3 ubiquitin transferase RNF43) functions as a tumor suppressor, by exerting a predominant negative feedback mechanism in the Wnt/β-catenin signaling pathway. RNF43 inhibits Wnt/beta-catenin signaling by ubiquitinating Frizzled receptor and targeting it to the lysosomal pathway for degradation. |
| Synonyms |
E3 ubiquitin-protein ligase RNF43;RING finger protein 43;RING-type E3 ubiquitin transferase RNF43;Rnf43 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
